JBIO Phase 1 readout: a negative outcome, -11.6%

On June 1, 2026, Jade Biosciences, Inc. reached its Phase 1 readout. The result was a negative outcome, and the stock moved -11.6% in the window around the event. It had already run -13.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.